Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Immix Biopharma, Inc. announces a $125 million underwritten offering of common stock to fund NXC-201 development and working capital. The offering closes on September 30, 2026.
PUBLIC · IMMXSep 29, 2026
Amount Raised
$125 Million
Round Type
Post-IPO Equity
Los AngelesBiotechnologyHealth Care
Investors
Wellington ManagementRidgeback Capital Investments L.P.Janus Henderson InvestorsEventide Asset Management
Description
Immix Biopharma, Inc. has priced an underwritten registered offering of 11,363,637 shares at $11.00 per share, expecting gross proceeds of $125 million. The offering is intended to support NXC-201 development and general corporate purposes. J.P
Company Information
Company
Immix Biopharma
Location
Los Angeles, California, United States
About
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases. Our lead cell therapy is FDA IND cleared next generation CAR-T NXC-201, currently being evaluated in our ongoing Phase 1b/2 NEXICART-1 (NCT04720313) clinical trial, initiated in February 2021. NXC-201 has the potential to be the world’s first “Single-Day CRS” CAR-T (CRS median onset day 1, median duration 1 day), enabling the potential for a faster return home for patients and supporting ongoing expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and ODD by the European Commission (EMA) in AL Amyloidosis.
Fundz sees it the moment Immix Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Los AngelesBiotechnologyHealth Care